-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
4D Molecular Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q2 2025.
- 4D Molecular Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2025 was -$59.5M, a 40% decline year-over-year.
- 4D Molecular Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2025 was -$220M, a 67.9% decline year-over-year.
- 4D Molecular Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$188M, a 66.4% decline from 2023.
- 4D Molecular Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$113M, a 2.58% decline from 2022.
- 4D Molecular Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$110M, a 54.3% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)